Literature DB >> 30012004

Huntington's disease: Neuropsychiatric manifestations of Huntington's disease.

Anita My Goh1, Pierre Wibawa2, Samantha M Loi3, Mark Walterfang4, Dennis Velakoulis3, Jeffrey Cl Looi5.   

Abstract

OBJECTIVES: Huntington's disease (HD) is a profoundly incapacitating, and ultimately fatal, neurodegenerative disease. HD is presently incurable, so the current goal is to allow affected individuals to live as well as possible with the illness, to maximise functional independence and quality of life for the person with HD, their carers and family members. This clinical update review focuses on the common neuropsychiatric manifestations in HD, and outlines and evaluates the various neuropsychiatric facets of HD, including the aetiology, symptoms and diagnosis.
CONCLUSIONS: Neuropsychiatric symptoms can precede the classic motor clinical symptoms of HD (prodromal HD) by decades, and cause significant functional impairment. HD provides key insights and understanding into the organic psychiatric disorders, including contemporary clinical insights into the process of neurodegeneration and manifestation of neuropsychiatric symptoms.

Entities:  

Keywords:  Huntington’s disease; neuropsychiatric manifestations; neuropsychiatry; psychiatry

Mesh:

Year:  2018        PMID: 30012004     DOI: 10.1177/1039856218791036

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  2 in total

1.  Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shujun Chen; Tianyu Liang; Tao Xue; Shouru Xue; Qun Xue
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.003

2.  A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice.

Authors:  Christopher J Heath; Claire O'Callaghan; Sarah L Mason; Benjamin U Phillips; Lisa M Saksida; Trevor W Robbins; Roger A Barker; Timothy J Bussey; Barbara J Sahakian
Journal:  Front Neurol       Date:  2019-08-09       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.